
Am J Psychiatry 162:2379-2381, December 2005
doi: 10.1176/appi.ajp.162.12.2379
© 2005 American Psychiatric Association
Open-Label Trial of Riluzole in Generalized Anxiety Disorder
Sanjay J. Mathew, M.D.,
Jonathan M. Amiel, B.S.,
Jeremy D. Coplan, M.D.,
Heidi A. Fitterling, B.A.,
Harold A. Sackeim, Ph.D., and
Jack M. Gorman, M.D.
OBJECTIVE: There is a need to identify novel pharmacotherapies for anxiety disorders. The authors examined the safety and efficacy of riluzole, an antiglutamatergic agent, in adult outpatients with generalized anxiety disorder. METHOD: In an 8-week, open-label, fixed-dose study, 18 medically healthy patients with DSM-IV generalized anxiety disorder received treatment with riluzole (100 mg/day) following a 2-week drug-free period. The primary efficacy measure was the Hamilton Anxiety Rating Scale (HAM-A) score at endpoint. RESULTS: Twelve of the 15 patients who completed the trial responded positively to riluzole. At 8 weeks, eight of the 15 patients had HAM-A score indicating remission of their anxiety. The median time to response was 2.5 weeks. CONCLUSIONS: Riluzole appears to be an effective, well-tolerated, and rapidly acting anxiolytic medication for some patients with generalized anxiety disorder. Larger, placebo-controlled studies are indicated.
This article has been cited by other articles:

|
 |

|
 |
 
M. H. Pollack, M. W. Otto, P. P. Roy-Byrne, J. D. Coplan, B. O. Rothbaum, N. M. Simon, and J. M. Gorman
Novel Treatment Approaches for Refractory Anxiety Disorders
Focus,
September 1, 2008;
6(4):
486 - 495.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Get information about faster international access.
a>
Privacy Policy
Copyright © 2005
American Psychiatric Association.
All rights reserved.
Home
| Search
| Current Issue
| Past Issues
| Subscribe
| All APPI Journals
| Help
| Contact Us
|